Bladder cancer vaccine trial shows promise without chemo
NCT ID NCT05241340
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times
Summary
This study tests a new approach for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. The treatment combines an immunotherapy drug (sasanlimab) with targeted radiation to help the body's immune system fight the tumor before surgery. The goal is to see if this combination is safe and can lead to a complete response in the removed bladder tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77006, United States
Conditions
Explore the condition pages connected to this study.